TY - JOUR
T1 - Trans-biobank analysis with 676,000 individuals elucidates the association of polygenic risk scores of complex traits with human lifespan
AU - FinnGen
AU - Sakaue, Saori
AU - Kanai, Masahiro
AU - Karjalainen, Juha
AU - Akiyama, Masato
AU - Kurki, Mitja
AU - Matoba, Nana
AU - Takahashi, Atsushi
AU - Hirata, Makoto
AU - Kubo, Michiaki
AU - Matsuda, Koichi
AU - Murakami, Yoshinori
AU - Daly, Mark J.
AU - Kamatani, Yoichiro
AU - Okada, Yukinori
N1 - Funding Information:
We thank all the participants of BBJ, UKB and FinnGen. We thank A. Palotie for his support for the data analysis of FinnGen, B. M. Neale and N. Baya for sharing and discussing their idea on LOGO, and A. R. Martin for the PRS analysis on UKB. We thank K. Yamamoto for supporting our analyses. This research was supported by the Tailor-Made Medical Treatment Program (the BBJ Project) of the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), the Japan Agency for Medical Research and Development (AMED). The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and nine industry partners (AbbVie, AstraZeneca, Biogen, Celgene, Genentech, GSK, MSD, Pfizer and Sanofi). The following biobanks are acknowledged for collecting the FinnGen project samples: Auria Biobank (https://www.auria.fi/biopankki/), THL Biobank (https://thl.fi/en/web/thl-biobank), Helsinki Biobank (https://www.terveyskyla.fi/helsinginbiopankki/), Northern Finland Biobank Borealis (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki), Finnish Clinical Biobank Tampere (https://www.tays.fi/biopankki), Biobank of Eastern Finland (https://ita-suomenbiopankki.fi), Central Finland Biobank (https://www.ksshp. fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (https://www.bloodservice.fi/Research%20Projects/biobanking), Terveystalo Biobank Finland (https://www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). Y.O. was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (15H05911, 19H01021), AMED (JP19gm6010001, JP19ek0410041, JP19ek0109413, and JP19km0405211), the Takeda Science Foundation, and the Bioinformatics Initiative of Osaka University Graduate School of Medicine, Osaka University. M.Kanai was supported by a Nakajima Foundation Fellowship and the Masason Foundation.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - While polygenic risk scores (PRSs) are poised to be translated into clinical practice through prediction of inborn health risks1, a strategy to utilize genetics to prioritize modifiable risk factors driving heath outcome is warranted2. To this end, we investigated the association of the genetic susceptibility to complex traits with human lifespan in collaboration with three worldwide biobanks (ntotal = 675,898; BioBank Japan (n = 179,066), UK Biobank (n = 361,194) and FinnGen (n = 135,638)). In contrast to observational studies, in which discerning the cause-and-effect can be difficult, PRSs could help to identify the driver biomarkers affecting human lifespan. A high systolic blood pressure PRS was trans-ethnically associated with a shorter lifespan (hazard ratio = 1.03[1.02–1.04], Pmeta = 3.9 × 10−13) and parental lifespan (hazard ratio = 1.06[1.06–1.07], P = 2.0 × 10−86). The obesity PRS showed distinct effects on lifespan in Japanese and European individuals (Pheterogeneity = 9.5 × 10−8 for BMI). The causal effect of blood pressure and obesity on lifespan was further supported by Mendelian randomization studies. Beyond genotype–phenotype associations, our trans-biobank study offers a new value of PRSs in prioritization of risk factors that could be potential targets of medical treatment to improve population health.
AB - While polygenic risk scores (PRSs) are poised to be translated into clinical practice through prediction of inborn health risks1, a strategy to utilize genetics to prioritize modifiable risk factors driving heath outcome is warranted2. To this end, we investigated the association of the genetic susceptibility to complex traits with human lifespan in collaboration with three worldwide biobanks (ntotal = 675,898; BioBank Japan (n = 179,066), UK Biobank (n = 361,194) and FinnGen (n = 135,638)). In contrast to observational studies, in which discerning the cause-and-effect can be difficult, PRSs could help to identify the driver biomarkers affecting human lifespan. A high systolic blood pressure PRS was trans-ethnically associated with a shorter lifespan (hazard ratio = 1.03[1.02–1.04], Pmeta = 3.9 × 10−13) and parental lifespan (hazard ratio = 1.06[1.06–1.07], P = 2.0 × 10−86). The obesity PRS showed distinct effects on lifespan in Japanese and European individuals (Pheterogeneity = 9.5 × 10−8 for BMI). The causal effect of blood pressure and obesity on lifespan was further supported by Mendelian randomization studies. Beyond genotype–phenotype associations, our trans-biobank study offers a new value of PRSs in prioritization of risk factors that could be potential targets of medical treatment to improve population health.
UR - http://www.scopus.com/inward/record.url?scp=85082751173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082751173&partnerID=8YFLogxK
U2 - 10.1038/s41591-020-0785-8
DO - 10.1038/s41591-020-0785-8
M3 - Article
C2 - 32251405
AN - SCOPUS:85082751173
SN - 1078-8956
VL - 26
SP - 542
EP - 548
JO - Nature medicine
JF - Nature medicine
IS - 4
ER -